Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wei Wang
Institution:
First People's Hospital of Foshan
Observed institution:
First People's Hospital of Foshan
ORCID:
0000-0001-5224-9359
Observed ORCID:
0000-0001-5224-9359
OpenAlex ID:
A5071596917
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2022
·
Feng Wang
, Ming-Ming He
, et al.
·
Clinical Cancer Research
·
73
Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer
2022
·
Fen Feng
, Huake Sun
, et al.
·
Journal of Oncology
·
22
PDF
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
2023
·
Feng Wang
, Ming-Ming He
, et al.
Show more works
View as search
Works count:
13
Citation count:
95
H-index:
2
I10-index:
2
Year
Topic
Type